Investigational Drug Information for TEW-7197
✉ Email this page to a colleague
What is the drug development status for TEW-7197?
TEW-7197 is an investigational drug.
There have been 15 clinical trials for TEW-7197.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 22nd 2019.
The most common disease conditions in clinical trials are Adenocarcinoma, Stomach Neoplasms, and Myelodysplastic Syndromes. The leading clinical trial sponsors are MedPacto, Inc., Samsung Medical Center, and AstraZeneca.
There are two US patents protecting this investigational drug and thirty-four international patents.
Summary for TEW-7197
| US Patents | 2 |
| International Patents | 34 |
| US Patent Applications | 59 |
| WIPO Patent Applications | 45 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2019-11-22) |
| Vendors | 52 |
Recent Clinical Trials for TEW-7197
| Title | Sponsor | Phase |
|---|---|---|
| Assessing Clinical Trial Outcome of Patients With Relapsed/Refractor Metastatic Osteosarcoma in Adolescents and Adults | MedPacto, Inc. | Phase 1/Phase 2 |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | Jennifer Eva Selfridge | Phase 1 |
| Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | AstraZeneca | Phase 2 |
Clinical Trial Summary for TEW-7197
Top disease conditions for TEW-7197
Top clinical trial sponsors for TEW-7197
US Patents for TEW-7197
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TEW-7197 | ⤷ Sign Up | 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same | Frequency Therapeutics, Inc. (Woburn, MA) | ⤷ Sign Up |
| TEW-7197 | ⤷ Sign Up | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance | CHILDREN'S MEDICAL CENTER CORPORATION (Boston, MA) PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TEW-7197
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TEW-7197 | European Patent Office | EP3313420 | 2035-06-25 | ⤷ Sign Up |
| TEW-7197 | Japan | JP2018519298 | 2035-06-25 | ⤷ Sign Up |
| TEW-7197 | Japan | JP2022028821 | 2035-06-25 | ⤷ Sign Up |
| TEW-7197 | Japan | JP6980534 | 2035-06-25 | ⤷ Sign Up |
| TEW-7197 | World Intellectual Property Organization (WIPO) | WO2016210292 | 2035-06-25 | ⤷ Sign Up |
| TEW-7197 | Australia | AU2011272149 | 2030-06-29 | ⤷ Sign Up |
| TEW-7197 | Brazil | BR112012033334 | 2030-06-29 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
